Trial · NCT02477696
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment | Baseline (Days -28 to -1) through 55.2 months (maximum observed duration) | ITT population included all participants randomized and were analyzed according to the arm to which they were randomly assigned. | Months | MEDIAN |
| SECONDARY | Number of Participants With Treatment-emergent Infections Grade >= 3 | Day 1 through 83.5 months (maximum observed duration) | Safety population included all participants who received at least one dose of study drug and were analyzed as treated. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Treatment-emergent Richter's Transformation | Day 1 through 83.5 months (maximum observed duration) | Safety population included all participants who received at least one dose of study drug and were analyzed as treated. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Treatment-emergent Atrial Fibrillation | Day 1 through 83.5 months (maximum observed duration) | Safety population included all participants who received at least one dose of study drug and were analyzed as treated. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Overall Survival (OS) | Baseline (Days -28 to -1) through 83.7 months (maximum observed duration) | ITT population included all participants randomized and were analyzed according to the arm to which they were randomly assigned. | Months | MEDIAN |
| SECONDARY | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Day 1 through 83.5 months (maximum observed duration) | Safety population included all participants who received at least one dose of study drug and were analyzed as treated. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Treatment-emergent Laboratory Abnormalities | Day 1 through 83.5 months (maximum observed duration) | Safety population included all participants who received at least one dose of study drug and were analyzed as treated. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Abnormal Vital Signs Reported as TEAEs | Day 1 through 83.5 months (maximum observed duration) | Safety population included all participants who received at least one dose of study drug and were analyzed as treated. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Percentage of Participants With Lymphocytosis | Day 1 through 83.5 months (maximum observed duration) | Safety population included all participants who received at least one dose of study drug and were analyzed as treated. | Percentage of participants | NUMBER |
| SECONDARY | Number of Participants With Electrocardiogram (ECG) Abnormality at Baseline | Baseline (Days -28 to -1) | Safety population included all participants who received at least one dose of study drug and were analyzed as treated. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Shift From Baseline to Worst (Grade 3 and 4) Postbaseline in Eastern Cooperative Oncology Group (ECOG) Performance Status | Baseline (Days -28 to -1) through 83.5 months (maximum observed duration) | Safety population included all participants who received at least one dose of study drug and were analyzed as treated. Here, number of participants analyzed (N) signified those participants who had a baseline value and at least 1 postbaseline value of ECOG performance status score during the study. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02477696/outcomes